[NFS-03] Neuroscience Frontier Symposium 03「Co-evolution of imaging and fluid biomarkers toward stratification of neurological disorders」

[NFS-03-3] アルツハイマー病におけるタウ病変を反映する新規血漿リン酸化タウアッセイの開発

互 健二, 建部 陽嗣, 樋口 真人, 徳田 隆彦 (量子科学技術研究開発機構 脳機能イメージング研究部)

Dr. Tagai obtained his M.D. from The Jikei University of Medicine in 2009 and trained in Psychiatry at The Jikei University Hospital. He conducted several neuroimaging studies on neuropsychiatric symptoms of dementia.
In 2016, he entered the Ph.D. program and enrolled in the development of novel tau PET ligand, 18F-PM-PBB3, as an internship student at QST.
In 2021, the FIH of 18F-PM-PBB3 were published in “Neuron,” and he received a Ph.D. degree. This publication led to his receiving the Alzheimer's Association International de Leon Prize in Neuroimaging.
In 2023, he presented his research on a novel blood biomarker reflecting tau PET at the AAIC's oral session. For this work, he received the International Conference Presentation Award from the Japanese Society of Psychiatry and Neurology. In the same year, he released this research as a preprint on medRxiv.
Now, he is a researcher at QST conducting the Co-evolution of imaging and fluid biomarkers.